(Audio) Immunotherapy in Bladder Cancer: Practice-Changing Advances Every Urology Professional Should Know

In this episode of UroNurse, host Vic Senese, RN, BSN, FAUNA, is joined by Matthew Galsky, MD, an internationally recognized expert in genitourinary oncology, to discuss the rapidly evolving role of immunotherapy in bladder cancerand how practice-changing advances are moving from clinical trials into everyday patient care.

Bladder cancer treatment has entered a new era. Immune checkpoint inhibitors, antibody-drug conjugates, targeted therapies, and emerging treatment combinations are changing how clinicians approach patients with muscle-invasive bladder cancer (MIBC), metastatic urothelial carcinoma, and advanced bladder cancer.

In this conversation, Dr. Galsky discusses important developments in bladder cancer immunotherapy and the implications for urology, oncology, and multidisciplinary patient care.

• The current role of immunotherapy in bladder cancer
• How immune checkpoint inhibitors are changing treatment strategies
• The evolution of treatment for advanced and metastatic urothelial carcinoma
• Practice-changing clinical trial results
• How new therapies are being incorporated into clinical practice
• Immunotherapy before and after surgery
• Treatment considerations for muscle-invasive bladder cancer
• Advances in treatment for patients who are not candidates for traditional approaches
• The expanding role of combination therapies
• Antibody-drug conjugates and their impact on bladder cancer treatment
• How clinicians should think about rapidly emerging treatment options
• The importance of multidisciplinary collaboration between urology, medical oncology, radiation oncology, and nursing
• What these advances mean for bladder cancer patients and their families
• What urology nurses and other healthcare professionals should know about the changing treatment landscape
• The future direction of bladder cancer research and immunotherapy

For decades, treatment options for advanced bladder cancer were relatively limited. Today, clinicians have an increasingly sophisticated range of systemic therapies and treatment combinations.

Understanding these developments is particularly important for urology nurses, advanced practice providers, urologists, medical oncologists, and other healthcare professionals who care for patients throughout the bladder cancer journey.

This episode provides an educational discussion of the science, clinical evidence, and evolving treatment strategies behind modern bladder cancer immunotherapy.

Whether you are a healthcare professional looking to stay current on urothelial carcinoma treatment, a urology nurse following advances in oncology, or a patient seeking to better understand the rapidly changing bladder cancer treatment landscape, this discussion provides valuable perspective from an expert in genitourinary oncology.

Hosted by Vic Senese, RN, BSN, FAUNA

🎙️ Guest: Matthew Galsky, MD

Subscribe to the UroNurse YouTube channel for more interviews, clinical education, urology news, and discussions with leading experts in urologic healthcare:

Subscribe to UroNurse on YouTube

The expert's opinions in this communication are personal and not representative of any organization. They are for informational purposes only, not official guidance. Viewers are advised to use their judgment, seek additional advice, and take responsibility for any actions based on these opinions.

Topics discussed include:Why this mattersKeywords